Kali, Inc. (KALY) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Kali, Inc. (KALY) trades at $0.0001. Kali, Inc. , operating as Kali-Extracts, Inc. , focuses on researching and developing cannabis treatments for various illnesses and chronic pain. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 18, 2026Analyst Coverage for KALY: KALY does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates KALY against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
Not enough scored data yet to form a council read on KALY.
How is this calculated? →Kali, Inc. (KALY) Healthcare & Pipeline Overview
Kali, Inc., formerly VLOV Inc., researches and develops cannabis-based treatments and wellness products, operating in the specialty and generic drug manufacturing sector. Based in Dallas, Texas, the company caters to patients seeking alternative therapies for various illnesses and chronic pain management, facing competition in the evolving cannabis market.
What Is the Investment Thesis for KALY?
Kali, Inc. presents a speculative investment opportunity within the cannabis-based treatment sector. The company's focus on research and development could yield innovative products, driving revenue growth. A key value driver is the potential for expansion into new markets as cannabis legalization progresses. However, the company's negative P/E ratio of -4.28 and negative profit margin of -18.2% indicate financial instability. The company's beta of -72.35 suggests high volatility, and its lack of dividend payouts offers no immediate return for investors. The company's small market cap of $0.00B indicates high risk. Success hinges on navigating regulatory hurdles and achieving profitability.
Based on FMP financials and quantitative analysis
KALY Key Highlights
Kali, Inc. operates in the cannabis-based treatment sector, focusing on research and development of pharmaceuticals, cannabis extracts, and health and wellness products.
- The company's negative P/E ratio of -4.28 indicates that it is currently not profitable.
- Kali, Inc.'s profit margin is -18.2%, reflecting challenges in achieving profitability.
- The company's gross margin is 22.0%, indicating the percentage of revenue exceeding the cost of goods sold.
- With a beta of -72.35, KALY exhibits high volatility compared to the broader market.
Who Are KALY's Competitors?
KALY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| INNPF INNOCAN PHARMA Corp | $1.60 | -8.05% | $7.20M | 61 |
| GENH Generation Hemp, Inc. | $0.22 | +0.00% | $25.3M | 63 |
| GBLP Global Pharmatech, Inc. | $0.08 | +0.00% | $33.3M | 62 |
| ETST Earth Science Tech, Inc. | $0.12 | +14.45% | $35.3M | 61 |
| GDNSF Goodness Growth Holdings, Inc. | $0.45 | +0.00% | $61.1M | 64 |
| MNNGF Baijin Life Science Holdings Limited | $0.08 | +0.00% | $74.6M | 63 |
| SHIEF Shield Therapeutics plc | $0.07 | +0.00% | $75.3M | 62 |
| CNVCF BioHarvest Sciences Inc. | $6.30 | +0.00% | $109M | 66 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are KALY's Key Strengths?
Focus on research and development of cannabis-based treatments.
- Proprietary cannabis formulations and intellectual property.
- Established presence in the cannabis market.
- Potential for growth in the expanding cannabis industry.
What Are KALY's Weaknesses?
Negative P/E ratio and profit margin indicate financial instability.
- High volatility compared to the broader market.
- Reliance on regulatory approvals for cannabis-based products.
- Limited financial resources compared to larger competitors.
What Could Drive KALY Stock Higher?
Potential regulatory approvals for new cannabis-based treatments.
- Expansion into new markets as cannabis legalization progresses.
- Development of strategic partnerships and acquisitions to expand product portfolio.
What Are the Key Risks for KALY?
Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Stringent regulations and compliance requirements in the cannabis industry.
- Intense competition from established pharmaceutical companies and emerging cannabis businesses.
- Fluctuations in cannabis prices and supply chain disruptions.
- Negative public perception of cannabis use.
What Are the Growth Opportunities for KALY?
- Expansion into New Markets: As cannabis legalization continues to spread across the United States and globally, Kali, Inc. has the opportunity to expand its geographic reach and tap into new customer bases. This includes entering states and countries that have recently legalized cannabis for medicinal or recreational purposes. The global legal marijuana market is projected to reach $90.4 billion by 2026, creating significant growth potential for companies like Kali, Inc.
- Development of Novel Cannabis Treatments: Kali, Inc.'s focus on research and development positions it to create innovative cannabis-based treatments for a variety of medical conditions. By investing in scientific research and clinical trials, the company can develop proprietary formulations and delivery methods that differentiate it from competitors. This includes targeting specific medical conditions such as chronic pain, anxiety, and neurological disorders. The market for cannabis-based pharmaceuticals is expected to grow significantly in the coming years.
- Strategic Partnerships and Acquisitions: Kali, Inc. can pursue strategic partnerships and acquisitions to expand its product portfolio, market reach, and technological capabilities. This includes collaborating with other cannabis companies, pharmaceutical companies, and research institutions. By partnering with established players in the industry, Kali, Inc. can gain access to new markets, technologies, and expertise. This strategy can accelerate the company's growth and enhance its competitive position.
- Focus on Health and Wellness Products: In addition to pharmaceuticals, Kali, Inc. can expand its offerings of health and wellness products that incorporate cannabis extracts. This includes developing products such as CBD oils, topicals, and edibles that cater to consumers seeking natural health solutions. The market for CBD products is growing rapidly, driven by increasing consumer awareness of the potential health benefits of CBD. By focusing on high-quality, safe, and effective products, Kali, Inc. can capture a significant share of this market.
- Direct-to-Consumer Sales and Online Presence: Kali, Inc. can enhance its direct-to-consumer sales channels and online presence to reach a wider audience and build brand awareness. This includes developing an e-commerce platform that allows customers to purchase products directly from the company. By investing in digital marketing and social media, Kali, Inc. can engage with customers, promote its products, and build a loyal customer base. This strategy can reduce reliance on third-party retailers and increase profit margins.
What Are KALY's Competitive Advantages?
- Proprietary cannabis formulations developed through research and development.
- Intellectual property protection for its cannabis-based treatments.
- Established relationships with cannabis cultivators and suppliers.
What Does KALY Do?
Kali, Inc., doing business as Kali-Extracts, Inc., was founded with the vision of developing cannabis-based treatments for a range of medical conditions. Originally named VLOV Inc., the company rebranded to Kali, Inc. in February 2016, signaling its strategic shift towards the cannabis sector. Headquartered in Dallas, Texas, Kali, Inc. focuses on the research, development, and distribution of pharmaceuticals, cannabis extracts, and health and wellness products. The company's core mission revolves around providing alternative treatment options for individuals suffering from various illnesses, diseases, and chronic pain. Kali-Extracts' product line encompasses a variety of cannabis-derived formulations designed to address specific medical needs. These products range from pharmaceutical-grade medications to natural health supplements, all leveraging the therapeutic properties of cannabis. The company's research and development efforts are geared towards identifying novel applications of cannabis in treating conditions such as chronic pain, inflammation, and neurological disorders. Kali, Inc. operates primarily within the United States, targeting markets where cannabis use is legal for medicinal or recreational purposes. As a player in the specialty and generic drug manufacturing industry, Kali, Inc. faces competition from both established pharmaceutical companies and emerging cannabis businesses. The company differentiates itself through its focus on research-driven product development and its commitment to providing high-quality, safe, and effective cannabis-based treatments. The company has 171 employees.
What Products and Services Does KALY Offer?
- Researches and develops cannabis treatments for various illnesses.
- Develops cannabis treatments for diseases.
- Develops cannabis treatments for chronic pain.
- Provides pharmaceuticals containing cannabis extracts.
- Offers health and wellness products containing cannabis extracts.
- Engages in the cultivation and processing of cannabis plants.
How Does KALY Make Money?
- Develops and sells cannabis-based pharmaceuticals for specific medical conditions.
- Produces and distributes cannabis extracts for use in health and wellness products.
- Generates revenue through the sale of its products to patients and consumers.
What Industry Does KALY Operate In?
Kali, Inc. operates within the rapidly evolving cannabis industry, specifically in the niche of cannabis-based treatments. The market is characterized by increasing acceptance of cannabis for medicinal and recreational use, driving growth in demand for related products and services. However, the industry is also subject to stringent regulations and intense competition. Kali, Inc. competes with established pharmaceutical companies and emerging cannabis businesses, navigating a complex landscape of regulatory compliance and market dynamics. The global legal marijuana market is projected to reach $90.4 billion by 2026, according to Fortune Business Insights.
Who Are KALY's Key Customers?
- Individuals seeking alternative treatments for illnesses and diseases.
- Patients suffering from chronic pain.
- Consumers interested in health and wellness products containing cannabis extracts.
Financial Health
Kali, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 3.95 places it in the safe zone, indicating low near-term bankruptcy risk.
Key Financial Metrics
Return on equity for Kali, Inc. stands at 3.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -28.7%, showing how much profit it generates from its asset base. Its free cash flow yield is -0.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.07 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -11.7%, the inverse of the P/E and a quick read on earnings relative to price.
Company Profile
Kali, Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Dallas, US. The company is led by CEO Frederick Ferri. KALY has traded publicly since 2008.
KALY Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Focus on research and development of cannabis-based treatments.
- Proprietary cannabis formulations and intellectual property.
- Established presence in the cannabis market.
- Potential for growth in the expanding cannabis industry.
Bear Case
- Negative P/E ratio and profit margin indicate financial instability.
- High volatility compared to the broader market.
- Reliance on regulatory approvals for cannabis-based products.
- Limited financial resources compared to larger competitors.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
KALY Latest News
No recent news available for KALY.
KALY Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for KALY.
Price Targets
Wall Street price target analysis for KALY.
KALY MoonshotScore
What does this score mean?
The MoonshotScore rates KALY 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Frederick Ferri
CEO
Frederick Ferri serves as the CEO of Kali, Inc., bringing leadership to a team of 171 employees. Information regarding his specific career history, education, and previous roles is not available in the provided data. However, as CEO, he is responsible for guiding the company's strategic direction, overseeing its operations, and driving its growth in the cannabis-based treatment sector.
Track Record: Due to limited information, Frederick Ferri's specific achievements, strategic decisions, and company milestones under his leadership cannot be detailed. His role involves navigating the company through the evolving cannabis market, overseeing research and development efforts, and managing the company's financial performance.
KALY OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Kali, Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, making it more difficult for investors to assess their financial health and performance. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies face fewer regulatory requirements, resulting in increased risk and potential for fraud. Investing in OTC Other stocks requires a higher degree of due diligence and risk tolerance.
- OTC Tier: OTC Other
- Limited financial disclosure and transparency due to the OTC Other tier.
- Potential for low trading volumes and wide bid-ask spreads.
- Higher risk of fraud and manipulation compared to major exchanges.
- Limited regulatory oversight and investor protection.
- Greater price volatility due to speculative trading and lack of institutional interest.
- Verify the company's financial reporting status and access available financial statements.
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Review the company's filings with the Securities and Exchange Commission (SEC).
- Consult with a financial advisor to assess the risks and potential rewards.
- Monitor news and developments related to the company and the cannabis industry.
- Understand the potential impact of regulatory changes on the company's business.
- The company has been in operation since 2016.
- Kali, Inc. has 171 employees.
- The company is actively engaged in research and development of cannabis-based treatments.
- Kali, Inc. has a gross margin of 22.0%.
Kali, Inc. Healthcare Stock: Key Questions Answered
What does Kali, Inc. do?
Kali, Inc., operating as Kali-Extracts, Inc., is focused on the research, development, and distribution of cannabis-based treatments and wellness products. The company aims to provide alternative treatment options for various illnesses, diseases, and chronic pain. Kali, Inc. offers pharmaceuticals, cannabis extracts, and health and wellness products, targeting markets where cannabis use is legal for medicinal or recreational purposes.
What are the main risks for KALY?
The main risks for Kali, Inc. include stringent regulations and compliance requirements in the cannabis industry, intense competition from established pharmaceutical companies and emerging cannabis businesses, and potential fluctuations in cannabis prices and supply chain disruptions.
What are the key factors to evaluate for KALY?
Evaluate KALY on fundamentals, analyst consensus, and risk factors. Kali, Inc. presents a speculative investment opportunity within the cannabis-based treatment sector. Not financial advice.
How frequently does KALY data refresh on this page?
KALY's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven KALY's recent stock price performance?
Kali, Inc. (KALY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on research and development of cannabis-based treatments. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider KALY overvalued or undervalued right now?
Kali, Inc. (KALY) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research KALY before investing?
Before investing in Kali, Inc. (KALY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding KALY to a portfolio?
Key strength of Kali, Inc. (KALY): Focus on research and development of cannabis-based treatments. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on limited data available.
- OTC market data may be less reliable than major exchanges.